Introduction
============

Chronic periodontitis (CP) is the most common disease that causes destruction of periodontal tissue ([@ref-29]). Gram-negative bacterial infection is the main cause for CP, and the host reaction following infection forms a basis for periodontitis. In this regard, T cells, macrophages, epithelium cells and proinflammatory cytokines such as interleukin (IL)-1*β*, IL-6, IL-8 and tumor necrosis factor-*α* ([@ref-22]; [@ref-31]) are related to immunoreaction and together function as an immunological barrier for pathogenic bacteria in periodontitis. Many studies have shown the role of cytokines in periodontitis ([@ref-14]; [@ref-30]). The IL-17 cytokine family includes six members (IL-17A--F), and IL-17A is commonly referred to as IL-17. Recent reports have shown that IL-17 is produced by mainly T helper (Th) 17 cells ([@ref-1]; [@ref-11]; [@ref-12]; [@ref-33]) and interferon (IFN)-*γ* produced by Th1 cells ([@ref-34]) may play an important destructive role in periodontitis. [@ref-13] reported that Th1 and Th17 cytokines have intimate involvement in the progression of periodontitis. In addition, Th17 cells and IL-17 might be a key inducer for the alveolar bone breakdown in periodontitis ([@ref-11]). Several studies have observed the IL-17 or IFN-*γ* producing T cell population of peripheral blood in CP patients ([@ref-4]; [@ref-5]; [@ref-23]; [@ref-32]); however, the results are inconclusive as to whether these cells are increased or not.

The role of Th17 cells in periodontitis is still controversial, as Th17 cells have been shown to play a protective and destructive role in infectious diseases and autoimmune diseases ([@ref-8]; [@ref-19]; [@ref-26]; [@ref-40]). A master regulator gene of Th17 cells is the gene encoding ROR, a member of a nuclear receptor superfamily. ROR has three subtypes, ROR*α*, ROR*β* and ROR*γ* t encoded by *RORA, RORB* and *RORC*, respectively ([@ref-16]). Th17 differentiation was significantly decreased in a ROR*γ* t-deficient mouse *in vitro* and *in vivo* studies, however the deficiency of ROR*γ* t did not completely suppress Th17 differentiation ([@ref-16]). This suggests that ROR*γ* t is a critical factor, but an additional transcription factor may also promote Th17 differentiation. Another study reported that ROR*α* regulates Th17 differentiation and both ROR*γ* t and ROR*α* deficiency leads to complete abolishment of Th17 differentiation ([@ref-39]).

Anti-inflammatory cytokines from Th2 cells and regulatory T (Treg) cells have been thought to counteract the periodontal disease progression pathways ([@ref-13]). However, the mechanism for controlling the severity of periodontitis is not clarified. IL-35 is a recently identified anti-inflammatory cytokine heterodimered with Epstein--Barr virus-induced gene 3 (EBI3) and IL-12p35 subunits ([@ref-9]). IL-35, produced by Treg cells, can downregulate the development of Th17 cell and inhibit autoimmune inflammation ([@ref-6]; [@ref-7]; [@ref-27]). IL-35 suppresses IL-17 production by inhibiting differentiation of Th17 cells, and thus plays a protective role in Th17-related diseases ([@ref-37]; [@ref-38]). Accordingly, IL-35 might have a beneficial effect in periodontitis. However, our previous study showed that both IL-35 and IL-17 were significantly upregulated in CP patients ([@ref-25]). Thus, the role of IL-35 in periodontitis is not clear, especially the direct effect of IL-35 on the function of Th17 cells. Therefore, in this preliminary study, we investigated the effect of IL-35 on Th17 cells derived from healthy volunteers, and found a direct inhibitory effect of IL-35 on Th17 cell induction and IL-17 production.

Materials & Methods
===================

Participants
------------

CP patients (with at least six teeth with probing pocket depth (PPD) ≥ 5 mm and clinical attachment level (CAL) ≥ 6 mm) and periodontal healthy adult volunteers were recruited from the outpatient population of the Aichi Gakuin University Dental Hospital, Japan from Mar 1 to May 31, 2015. Exclusion criteria were smoking within the past five years, antibiotic therapies during the previous six months, pregnancy and any systemic condition that could affect the progression of periodontitis (e.g., immunological disorders, diabetes and osteoporosis). Healthy volunteers exhibited no signs of clinical periodontal attachment loss with PPD ≤ 3 mm and full-mouth bleeding on probing score \<10%. One examiner recorded PPD and CAL as well as demographic data for all participants.

Ethics statement
----------------

All participants signed an informed consent form at the beginning of this study, and the study received approval from the Ethics Committee of Aichi Gakuin University (approval no. 390) in accordance with the World Medical Association Declaration of Helsinki, as revised in 2013.

CD4^+^T cell isolation from peripheral blood
--------------------------------------------

Peripheral blood was sampled from three healthy volunteers and three CP patients. CD4^+^T cells were purified by the CD4^+^ T cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and the autoMACS (Miltenyi Biotec), according to the manufacturer's manual (routine purity; 98%).

Flow cytometry
--------------

For intracellular cytokine staining, the cells were restimulated for 4 h with 50 ng/mL phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich, Saint Louis, MO, USA) and 500 ng/mL ionomycin (Sigma-Aldrich) in the presence of Brefeldin A (eBioscience, San Diego, CA, USA), as recommended by the manufacturer. The cells were first stained with APC-eFluor780 conjugated anti-CD4 antibody (Ab), then permeabilized with Perm/Fix solution (eBioscience), and finally stained with PE conjugated anti-IL-17A, eFluor450 conjugated anti-IFN-*γ* and PE-Cy5 conjugated anti-Foxp3 Abs (eBioscience). Data were acquired using a MACSQuant Analyzer 10 (Miltenyi Biotec). Isotype-matched Abs (directly conjugated) were used as controls.

Th17 cell differentiation and cell culture
------------------------------------------

Th17 cell differentiation experiments were carried out using samples from three healthy volunteers. We compared Th17 cell differentiation with the cytokine cocktail or rIL-23. CD4^+^T cells (5×10^5^  cells/mL) were cultured for five days in round-bottom 96-well plates with CD3/CD28 T cell expander beads in the presence of cytokine cocktail (recombinant transforming growth factor- *β* (rTGF-*β*) (10 ng/mL), rIL-6 (10 ng/mL), rIL-1 *β* (10 ng/mL), anti--IFN-*γ* (0.5 mg/mL), anti-IL-2 (1 mg/mL) and anti-IL-4 (0.5 mg/mL)) or rIL-23 (40 ng/mL) (Peprotech, Rocky Hill, NJ, USA). After Th17 cell differentiation, Th17 cells were cultured with or without rIL-35 (1 ng/mL) (Peprotech). The cells were collected after 2 h of culture with rIL-35 for polymerase chain reaction (PCR), and the supernatant was collected after 24 h of culture with rIL-35 for enzyme-linked immunosorbent assay (ELISA).

RNA isolation and quantitative PCR analysis
-------------------------------------------

Total RNA from Th17 cells was immediately isolated using the NucleoSpin RNA II system (Macherey-Nagel, Dueren, Germany) according to the manufacturer's instructions. The quality of the total RNA was evaluated by measuring the A260/A280nm ratio using a fluorospectrometer (NanoDrop ND-1000; Thermo Scientific, Wilmington, DE, USA). cDNA was synthesized using 13.2 µL of total RNA (40--60 ng/µL), 6 µL of 5× First Strand buffer, 3 µL of DTT (0.1 mM), 6 µL of dNTP Mix (2.5 mM), 0.75 µL of random primers, 1 µL of SuperScript III Reverse Transcriptase (200 units) (Invitrogen, Carlsbad, CA, USA) and 0.5 µL of Ribonuclease Inhibitor (Invitrogen). The reaction was incubated at 37°C for 60 min followed by 5 min at 95°C. To quantify the amount of mRNA, quantitative PCR (qPCR) analyses were performed in a volume of 50 µL containing 2.5 µg cDNA, 28.2 µL TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA), 2.2 µL of each of TaqMan Gene Expression assay (Applied Biosystems) (*IL17A* (Hs99999082_m1), *RORA* (Hs00536545_m1), *RORC* (Hs01076122_m1) and *ACTB* (Hs99999903_s1)) on ABI Prism 7000 Sequence Detection System software version 1.0 (Applied Biosystems) with MicroAmp Optical 96-well Reaction Plate and MicroAmp optical adhesive film (Applied Biosystems). The cycle parameters were as follows: 10 min at 95°C, then 40 cycles of 15 s at 95°C and 1 min at 60°C. Quantification was performed using the ΔΔC~q~ method as previously described ([@ref-17]). Briefly, the fold change between mRNA expression levels was determined as follows: fold change =2^−ΔΔCq^, where ΔΔC~q~ = \[(C~q~ target − C~q~*ACTB*(treatedgroup)) − (C~q~target − C~q~*ACTB*(control group))\], where "C~q~" denotes the quantification cycle.

ELISA
-----

IL-17A protein levels in the culture supernatants were measured by human IL-17A ELISA Kits (Diaclone, France) according to the manufacturer's instructions. The values were recorded at a wavelength of 450 nm and a standard curve was plotted on a linear graph. The values were then calculated from the standard curve.

Statistical analysis
--------------------

All data are expressed as mean  ±  SE. Statistical calculations were carried out using GraphPad Prism (Graph Pad Software, San Diego, CA, USA). All data were compared using one-way repeated measures ANOVA followed by the non-parametric Bonferroni multiple comparisons test. Values of *P* \< 0.05 were considered significant.

Results
=======

T cell population in peripheral blood from CP patients
------------------------------------------------------

We first investigated pathogenic T cell populations in periodontitis by evaluating IL-17A and IFN-*γ* producing CD4^+^T cells in CP patients. We recruited three healthy participants (mean age, 62.0  ±  2.6; one male and two females) and three CP patients (mean age, 52.3  ±  3.7; three females). In healthy participants, the mean PPD was 2.1  ±  0.2 mm and CAL was 2.6  ±  0.2 mm. In CP patients, the mean PPD was 4.0  ±  0.9 mm and CAL was 4.4  ±  1.3 mm. To clarify whether CP affects CD4^+^T cell populations, IL-17A^+^CD4^+^, IFN-*γ*^+^CD4^+^ and Foxp3^+^CD4^+^ T cells in peripheral blood were monitored using flow cytometry. The proportions of IL-17A^+^CD4^+^, IFN-*γ*^+^CD4^+^ and Foxp3^+^CD4^+^ T cells in healthy controls and CP patients were 4.5  ±  1.0%, 22.8  ±  5.5%, 9.4  ±  0.7%, and 7.7  ±  1.9%, 21.3  ±  1.7%, 9.7  ±  0.5%, respectively. One representative dot plot from each group is shown in [Fig. 1](#fig-1){ref-type="fig"}. No significant differences were observed in any T cell populations between the small sample groups tested.

![Percentage of IL-17A, IFN-*γ* and Foxp3 expressing CD4^+^ T cells in peripheral blood from healthy volunteers and CP patients.\
Representative dot plots of IL-17A or IFN-*γ* positive CD4^+^ T cells and IL-17A or Foxp3 positive CD4^+^ T cells in the peripheral blood from healthy volunteers and CP patients. Dot plots are representative of three individuals per group.](peerj-05-2999-g001){#fig-1}

IL-35 may directly inhibit IL-17 production in Th17 cells via ROR*α* and ROR*γ*t inhibition
-------------------------------------------------------------------------------------------

Because no report has shown the direct effect of IL-35 on Th17 cells, we next examined this question. Currently, two major methods are used to induce Th17 cells from CD4^+^ T cells ([@ref-20]; [@ref-35]). One is induction by a cytokine cocktail including TGF-*β*, IL-6, IL-1*β*, anti-IFN-*γ* Ab, anti-IL-2 Ab and anti-IL-4 Ab; the second involves addition of rIL-23. We used CD4^+^ T cells in peripheral blood from three healthy volunteers and monitored the expression of master genes for Th17 cells during the two induction strategies. The cytokine cocktail group demonstrated significantly increased expression levels of *RORA* ([Fig. 2A](#fig-2){ref-type="fig"}) and *RORC* ([Fig. 2B](#fig-2){ref-type="fig"}) mRNA compared with the control (*P* \< 0.01). In contrast, there were no significant changes of *RORA* and *RORC* mRNA expression in the IL-23 treatment group. These results confirmed some reports showing that TGF-*β* and IL-6 but not IL-23 induces Th17 cell differentiation ([@ref-24]; [@ref-36]). Thus, we chose the cytokine cocktail induction method for the following experiments.

![Expression levels of *RORA* and *RORC* mRNA in two Th17 cell differentiation strategies.\
CD4^+^ T cells in peripheral blood from three healthy volunteers were incubated with a cytokine cocktail or rIL-23 for Th17 cell differentiation. *RORA* (A) and *RORC* (B) mRNA levels were evaluated and normalized to *ACTB*. Values are shown as the mean ± standard error of three independent experiments. ^∗∗^*P* \< 0.01 , one-way repeated measures ANOVA followed by the non-parametric Bonferroni multiple comparisons test.](peerj-05-2999-g002){#fig-2}

We next tested the expression of *IL17A* mRNA in cytokine-induced Th17 cells with or without rIL-35 ([Fig. 3A](#fig-3){ref-type="fig"}). The expression of *IL17A* mRNA was significantly increased in the polarized Th17 cells (*P* \< 0.01), and the induction was significantly inhibited by addition of rIL-35 (*P* \< 0.01). We also examined the mRNA expression of *RORA* ([Fig. 3B](#fig-3){ref-type="fig"}) and *RORC* ([Fig. 3C](#fig-3){ref-type="fig"}). We confirmed a significant decrease of *RORA* and *RORC* mRNA expression by addition of rIL-35 (*P* \< 0.01) ([Figs. 3B](#fig-3){ref-type="fig"} and [3C](#fig-3){ref-type="fig"}). Thus, IL-35 might inhibit *IL17A* mRNA expression by inhibition of *RORA* and *RORC* mRNA expression.

![Effect of IL-35 on expression of *IL17A*, *RORA* and *RORC* mRNA.\
After Th17 cell differentiation by cytokine cocktail, cells were cultured with or without rIL-35 (1 ng/mL) for 2 h. *IL17A* (A), *RORA* (B) and *RORC* (C) mRNA expression was determined and normalized to *ACTB*. Values are shown as the mean ± standard error of three independent experiments. ^∗∗^*P* \< 0.01, one-way repeated measures ANOVA followed by the non-parametric Bonferroni multiple comparisons test.](peerj-05-2999-g003){#fig-3}

Finally, we investigated the levels of IL-17A production in Th17 cells with or without rIL-35 ([Fig. 4](#fig-4){ref-type="fig"}). We found significantly decreased levels of IL-17A production in the rIL-35-treated groups compared with untreated Th17 cells (*P* \< 0.05).

![Effect of IL-35 on IL-17A production in Th17 cell.\
After Th17 cell differentiation by cytokine cocktail, cells were cultured with or without rIL-35 (1 ng/mL) for 24 h and IL-17A production in the culture supernatant was evaluated. Values are shown as the mean ± standard error of three independent experiments. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01, one-way repeated measures ANOVA followed by the non-parametric Bonferroni multiple comparisons test.](peerj-05-2999-g004){#fig-4}

Discussion
==========

In this study, we found a direct inhibitory effect of IL-35 on IL-17 production in Th17 cells. IL-35 inhibited the expression of *RORA* and *RORC* mRNA during Th17 cell differentiation. These results suggest that IL-35 might inhibit ROR*α* and ROR*γ* t in Th17 cells. To the best of our knowledge, this is the first report on the direct effect of IL-35 on Th17 cells.

Previous studies have reported that Th17 cells in human periodontal tissue were increased in CP patients compared with healthy controls ([@ref-2]; [@ref-3]). Indeed, another group reported that the quantity of Th17 cells in peripheral blood from CP patients was significantly decreased after non-surgical periodontal therapy ([@ref-41]). Another study showed that the levels of several inflammatory cytokines were significantly increased in serum and gingival tissue from CP patients compared with healthy controls ([@ref-15]). However, data on an increase of Th17 cells in peripheral blood from patients with periodontitis remain inconclusive. In this study, there were no significant differences in any T cell populations between healthy controls and CP patients, although the percentage of IL-17A^+^CD4^+^ T cells in CP patients was slightly elevated (1.7 times) compared with that in healthy participants. A larger sample size might provide further insights, which will be performed in future research.

In this study, we found that IL-35 directly inhibited IL-17 production in Th17 cells. Several studies have reported that IL-35 inhibited Th17 cell differentiation and IL-17 production ([@ref-37]; [@ref-41]). Further, it has been proposed that IL-35 suppresses Th17 cell differentiation by stimulating IL-10-producing CD4^+^ T cells ([@ref-18]). Our previous results showed that IL-35 was significantly higher in gingival crevicular fluid (GCF) and gingival tissue from CP patients than those of healthy participants ([@ref-25]). Another group also demonstrated that IL-35 in GCF and serum of CP patients were significantly higher than the control group ([@ref-21]). Based on these results, we speculate that IL-35 might play important roles in the pathogenesis of periodontitis via suppression of Th17 cells. However, the direct inhibitory effect of IL-35 on Th17 cell induction and IL-17 production is not completely understood. However, [@ref-28] reported that the presence of IL-17^+^ cells in periodontal tissue was very low. This implies that the role of Th17 cells might be limited in periodontitis. Thus, careful consideration of the role of IL-35 in periodontitis will be necessary in the future.

Moreover, this is the first report to demonstrate that a part of this mechanism might be due to suppression of ROR*α* and ROR *γ*t . ROR*α* and ROR *γ*t are known as the Th17-specific transcription factors. Yang et al. reported that overexpression of ROR*α* promoted Th17 cell differentiation and IL-17 expression in mice. Furthermore, the authors also suggested that ROR*α* exerts a synergistic effect with ROR*γ*t in Th17 cell differentiation ([@ref-39]). Although [@ref-10] reported that Foxp3, a key transcription factor in the development and function of Treg cells, also inhibits ROR*α*-specific transcriptional activation in humans. The mechanisms leading to differentiation of Th17 cells have been well established in mice, they are still poorly understood in humans. The present results also suggest that IL-35 may suppress *RORA, RORC* and *IL17A* mRNA and IL-17 production through a direct effect on Th17 cells.

Conclusions
-----------

The present study suggests that IL-35 could directly suppress IL-17 expression via ROR*α* and ROR*γ*t inhibition to restrain the excessive immune response in inflammatory conditions such as periodontitis. Further studies are required to confirm this hypothesis.
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